Several months after forging a fresh path forward for its troubled Friedreich ataxia (FA) drug vatiquinone, PTC Therapeutics ...

Sage Therapeutics has seen another clinical trial go up in smoke. | Sage Therapeutics has seen another clinical trial go up ...

Mestag Therapeutics has been working to change how fibroblasts are activated and how they expand. Now, Merck & Co. | Mestag ...

Astellas has turned to AviadoBio to further boost its gene therapy pipeline, paying the British biotech $50 million in equity ...

Black Diamond Therapeutics has deprioritized one of its two clinical-stage lung cancer contenders, jettisoned two executives ...

The sun has set on Johnson & Johnson’s SunRISe-2 study. J&J called a halt to the phase 3 bladder cancer trial after an ...

Taking the mat is Judo Bio, an up-and-coming biotech armed with $100 million to develop oligonucleotide medicines targeting ...

Ceribell, the maker of a portable, brain-reading headset for emergency seizure care, aims to go public on the Nasdaq through ...

A startup that aims to deliver a blood test to identify a biomarker linked with a specific subtype of autism—and then ...

RNA biotech CAMP4 Therapeutics has marked out plans for a $67 million IPO, with inflammation-focused Upstream Bio pegging its ...

A year after the failure of an idiopathic pulmonary fibrosis candidate sent Galecto on a search for salvation, the ...

AstraZeneca has paid CSPC Pharmaceutical Group $100 million for a preclinical cardiovascular disease drug candidate. The deal ...